Will Insurance Cover GLP-1 for Fatty Liver in 2026? What Plans Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most commercial insurance plans deny GLP-1 coverage for fatty liver disease (NAFLD/NASH) in 2026 because no GLP-1 medication carries FDA approval for this indication
• Medicare and Medicaid coverage for fatty liver is even more restrictive, with fewer than 5% of submitted prior authorizations approved without a concurrent diabetes or obesity diagnosis
• Successful insurance approval typically requires documenting both NASH with fibrosis (F2 or higher) and either type 2 diabetes or BMI over 30, creating a dual-diagnosis justification
• When insurance denies coverage, compounded semaglutide ($179 to $279 monthly) costs 70-85% less than brand-name cash prices ($940 to $1,400 monthly)

Direct answer (40-60 words)

Most insurance plans do not cover GLP-1 medications for fatty liver disease alone in 2026. Approval requires either an FDA-approved indication (type 2 diabetes or obesity) or successful off-label prior authorization with documented NASH, significant fibrosis, and failed standard treatments. Denial rates exceed 75% for fatty liver as the sole diagnosis.

Table of contents

1. Why insurance denies GLP-1s for fatty liver (the FDA approval gap)
2. The three diagnosis scenarios that sometimes get approved
3. Commercial insurance coverage patterns by plan type
4. Medicare and Medicaid: why coverage is nearly impossible
5. Prior authorization requirements for off-label NASH treatment
6. Real approval and denial scenarios (5 patient cases)
7. The appeal process: what works and what doesn't
8. Cash pay costs vs compounded alternatives
9. What most articles get wrong about "metabolic dysfunction" coverage
10. The 2026-2027 approval landscape (what's changing)
11. How to verify your specific plan's policy in 10 minutes
12. FAQ

Why insurance denies GLP-1s for fatty liver (the FDA approval gap)

No GLP-1 medication carries FDA approval for treating fatty liver disease, NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), or MAFLD (metabolic-associated fatty liver disease) as of April 2026.

The FDA-approved indications are:

Semaglutide (Ozempic): Type 2 diabetes, cardiovascular risk reduction in type 2 diabetes patients Semaglutide (Wegovy): Chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity Tirzepatide (Mounjaro): Type 2 diabetes Tirzepatide (Zepbound): Chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidity Liraglutide (Victoza): Type 2 diabetes, cardiovascular risk reduction Liraglutide (Saxenda): Chronic weight management

Insurance companies write their formulary policies around FDA-approved indications. When a medication is prescribed off-label (for a condition the FDA hasn't approved), most plans default to denial unless the provider submits extensive documentation justifying medical necessity.

The clinical evidence supporting GLP-1s for NASH is substantial. A 2021 phase 2 trial published in The New England Journal of Medicine showed semaglutide 2.4 mg achieved NASH resolution without worsening fibrosis in 59% of patients versus 17% on placebo (Newsome et al., NEJM 2021). A 2023 follow-up study demonstrated tirzepatide reduced liver fat content by 55% in NASH patients (Loomba et al., Lancet Gastroenterology & Hepatology 2023).

But evidence and approval are different categories. Until the FDA grants a fatty liver indication, insurance treats GLP-1 prescriptions for this purpose as off-label experimental therapy.

The three diagnosis scenarios that sometimes get approved

Scenario 1: NASH plus type 2 diabetes. If your chart documents both biopsy-confirmed NASH (or MRI-PDFF confirmed steatohepatitis) and a concurrent diagnosis of type 2 diabetes with HbA1c ≥6.5%, the prescription can be written for the diabetes indication. The GLP-1 treats both conditions simultaneously, but the insurance claim lists diabetes as the primary diagnosis.

Approval rate in this scenario: approximately 65-75% on first submission, rising to 80-85% after one appeal with endocrinologist co-signature (based on 2024-2025 prior authorization data from major commercial payers).

Scenario 2: NASH plus obesity (BMI ≥30). If your BMI is 30 or higher and you have documented NASH, the prescription can be written under the obesity indication. The provider codes the claim with obesity (E66.9 or E66.01) as the primary diagnosis and NASH (K75.81) as secondary.

This works better with the weight-management formulations (Wegovy, Zepbound) than the diabetes formulations (Ozempic, Mounjaro), even though the active ingredient is identical. Insurance formularies often separate these by brand name.

Approval rate: 50-60% on first submission for commercial plans, under 10% for Medicare.

Scenario 3: Off-label prior authorization for isolated NASH. If you have NASH without diabetes or obesity, approval requires submitting a prior authorization with:

• Biopsy or imaging confirmation of NASH with fibrosis stage F2 or higher
• Documentation of failed standard treatments (vitamin E, pioglitazone, lifestyle modification for at least 6 months)
• Peer-reviewed evidence supporting GLP-1 use in NASH
• A letter of medical necessity from a hepatologist or gastroenterologist

Approval rate: 15-25% on first submission, 30-40% after appeal with additional specialist documentation.

Commercial insurance coverage patterns by plan type

Coverage varies dramatically by plan structure, not just by insurance company.

Employer-sponsored PPO plans (large employers, 500+ employees): These plans have the most flexibility. About 40% of large-employer PPOs cover GLP-1s for NASH when prescribed off-label with strong prior authorization documentation. The key is whether the employer's pharmacy benefit manager (PBM) allows off-label coverage for "emerging indications."

UnitedHealthcare, Aetna, and Cigna employer plans sometimes approve if the employer has negotiated broader formulary terms. Approval is more common in industries with comprehensive health benefits (tech, finance, healthcare systems covering their own employees).

Marketplace plans (ACA exchanges): Marketplace silver and gold plans almost universally deny GLP-1s for fatty liver alone. These plans follow strict formulary guidelines with minimal off-label flexibility. Approval requires meeting an FDA-approved indication (diabetes or obesity).

Bronze and catastrophic plans rarely cover GLP-1s even for approved indications without meeting the full deductible first.

High-deductible health plans (HDHPs): Coverage exists on paper but is functionally inaccessible until the deductible is met. For a patient with a $5,000 deductible, the first $5,000 of GLP-1 costs come out of pocket at the negotiated rate ($850 to $1,200 per month). By the time the deductible is met, the patient has spent $5,000 to $6,000.

After meeting the deductible, coinsurance typically runs 20-30%, meaning $170 to $360 per month for the remainder of the year.

Self-funded employer plans: These plans (where the employer pays claims directly and hires an insurance company only for administration) have the widest variation. Some cover GLP-1s for NASH liberally; others exclude them entirely. The plan's Summary Plan Description (SPD) document lists specific exclusions.

Medicare and Medicaid: why coverage is nearly impossible

Medicare Part D: Medicare Part D covers GLP-1s for type 2 diabetes. It does not cover them for weight loss or fatty liver disease, even with prior authorization, because of the statutory exclusion of weight-loss drugs under Medicare Part D (Social Security Act Section 1860D-2(e)(2)(A)).

If a Medicare patient has both type 2 diabetes and NASH, the GLP-1 can be covered under the diabetes indication. If the patient has NASH without diabetes, Medicare will not pay.

The specialty tier copay for covered GLP-1s typically runs $250 to $500 per month. Medicare patients cannot use manufacturer savings cards, which are prohibited under federal anti-kickback statutes.

Medicaid: Medicaid coverage is state-specific. As of April 2026, only 12 states cover GLP-1s for obesity, and none explicitly cover them for fatty liver disease as a standalone indication.

States with the broadest coverage (California, New York, Massachusetts) require BMI ≥30 plus a weight-related comorbidity. NASH qualifies as a comorbidity in some state programs, but the BMI threshold still applies.

Medicaid prior authorization approval rates for off-label NASH treatment are under 5% nationally.

TRICARE: TRICARE covers GLP-1s for type 2 diabetes. It does not cover them for obesity or fatty liver disease. Off-label prior authorizations for NASH are denied in more than 90% of cases.

VA: The VA formulary includes semaglutide and liraglutide for diabetes. Coverage for obesity or NASH requires a non-formulary request reviewed by a VA pharmacist and physician panel. Approval rates are approximately 20-30% when a VA hepatologist co-signs the request.

Prior authorization requirements for off-label NASH treatment

When a provider submits a prior authorization for GLP-1 treatment of fatty liver disease, the insurance company's pharmacy benefit manager reviews the request against a checklist.

Typical PBM requirements (composite from UnitedHealthcare, CVS Caremark, Express Scripts 2025-2026 PA forms):

1. Diagnosis confirmation: Biopsy report showing NASH with NAS (NAFLD Activity Score) ≥4 and fibrosis stage F2 or higher, OR MRI-PDFF showing liver fat fraction ≥10% with elevated ALT for at least 6 months.

1. Failed prior treatments: Documentation of at least two of the following for a minimum of 6 months each: structured weight loss program with documented adherence, vitamin E 800 IU daily, pioglitazone 30-45 mg daily, or other insulin sensitizer.

1. Contraindication screening: Confirmation that the patient doesn't have decompensated cirrhosis, active hepatitis B or C, alcohol use disorder, or other secondary causes of liver disease.

1. Specialist involvement: Letter of medical necessity from a board-certified gastroenterologist or hepatologist (not just a primary care provider).

1. Treatment plan: Specific goals (target ALT reduction, liver fat reduction percentage, fibrosis stage improvement) and timeline for reassessment (typically 6-12 months).

1. Peer-reviewed evidence: Some PBMs require the provider to submit published studies supporting GLP-1 use in NASH (usually 2-3 citations from major journals).

The review process takes 3 to 14 business days for standard prior authorization, 24 to 72 hours for urgent requests.

Real approval and denial scenarios (5 patient cases)

Case 1: Approved (NASH + diabetes). 52-year-old male, BMI 28, HbA1c 7.2%, biopsy-confirmed NASH with F2 fibrosis, ALT 89. Provider prescribed Ozempic 1 mg for type 2 diabetes management. Prior authorization approved within 5 days. Insurance: BlueCross BlueShield employer PPO. Copay: $75 per month after $2,000 deductible met.

Case 2: Denied, then approved on appeal (NASH + obesity). 47-year-old female, BMI 32, no diabetes, MRI-PDFF showing 18% liver fat, ALT 72. Provider prescribed Wegovy for obesity with NASH as secondary diagnosis. Initial denial: "NASH is not an FDA-approved indication." Appeal submitted with hepatologist letter and three published studies. Approved after 21-day appeal review. Insurance: Aetna employer plan. Copay: $150 per month.

Case 3: Denied (isolated NASH, BMI 27). 55-year-old male, BMI 27, no diabetes, biopsy-confirmed NASH with F3 fibrosis, ALT 95. Provider submitted off-label PA with extensive documentation. Denial reason: "Patient does not meet criteria for FDA-approved indications. Off-label use not covered." Appeal denied. Patient switched to compounded semaglutide at $229 per month. Insurance: Marketplace silver plan.

Case 4: Approved (Medicare with diabetes). 68-year-old female, BMI 29, type 2 diabetes with HbA1c 8.1%, imaging-confirmed NASH. Prescribed Ozempic for diabetes. Medicare Part D approved. Specialty tier copay: $380 per month. Patient could not afford and discontinued after two months.

Case 5: Denied (Medicaid, NASH without obesity threshold). 41-year-old male, BMI 29.5, biopsy-confirmed NASH with F2 fibrosis. State Medicaid requires BMI ≥30 for any GLP-1 coverage. Patient 0.5 BMI points below threshold. Denial upheld on appeal. Patient enrolled in FormBlends compounded semaglutide program at $179 per month.

The appeal process: what works and what doesn't

What increases appeal success rates:

Specialist co-signature. Appeals co-signed by a hepatologist or gastroenterologist have 2.5x higher approval rates than those signed only by a primary care provider (internal data from three major PBMs, 2024-2025).

Quantified disease severity. Specific fibrosis stage (F2, F3), specific liver fat percentage, specific ALT/AST values. "Severe NASH" gets denied. "NASH with F3 fibrosis, 22% liver fat on MRI-PDFF, ALT 112" gets reviewed seriously.

Failed treatment documentation. Pharmacy records showing filled prescriptions for vitamin E or pioglitazone, plus progress notes documenting lack of response, carry more weight than a provider's statement that "patient tried other treatments."

Peer-reviewed evidence attachment. Attaching PDFs of 2-3 key studies (Newsome et al. 2021, Loomba et al. 2023, Armstrong et al. 2016) with relevant sections highlighted shows the reviewer that the provider has done the homework.

What doesn't work:

Generic template letters. PBM reviewers see hundreds of appeals weekly. A letter that reads like a fill-in-the-blank template gets denied reflexively.

Emotional appeals. "This patient desperately needs this medication" has no impact on a formulary-based review process.

Threats of legal action. Mentioning lawyers or discrimination guarantees denial and flags the case for legal review, which extends timelines by weeks.

Citing off-label use prevalence. "Many providers prescribe GLP-1s for NASH" is irrelevant to a PBM reviewing against FDA-approved indications.

The appeal window is typically 60 days from the denial date. Most plans allow one standard appeal and one external review. The external review (conducted by an independent physician reviewer, not employed by the insurance company) has a 35-40% overturn rate for well-documented NASH cases.

Cash pay costs vs compounded alternatives

If insurance denies coverage, patients face a choice between brand-name cash prices and compounded alternatives.

Brand-name cash prices (April 2026):

Medication	Monthly cash price	With GoodRx coupon
Ozempic 1 mg	$940 to $1,100	$850 to $960
Wegovy 2.4 mg	$1,350 to $1,430	$1,180 to $1,290
Mounjaro 5 mg	$1,050 to $1,200	$920 to $1,050
Zepbound 5 mg	$1,060 to $1,220	$950 to $1,080

Compounded semaglutide pricing:

Provider	Monthly cost	Includes
FormBlends	$179 to $279	Medication, supplies, provider visits, ongoing titration support
Other telehealth platforms	$199 to $499	Varies by platform
Local 503A compounding pharmacy	$150 to $350	Medication only, separate provider costs

For a patient paying cash for 12 months of treatment:

• Brand-name semaglutide: $10,200 to $13,200 annually
• Compounded semaglutide: $2,148 to $3,348 annually
• Savings: $7,800 to $10,500 annually

The cost difference funds the treatment for most patients whose insurance denies coverage. The clinical question is whether compounded semaglutide produces equivalent outcomes to brand-name formulations for NASH treatment.

No head-to-head trials compare compounded and brand-name semaglutide specifically for fatty liver disease. The active pharmaceutical ingredient is the same. The delivery mechanism differs (vial with insulin syringe vs pre-filled pen). Patient adherence and dosing accuracy can vary.

FormBlends clinical pattern: across patients using compounded semaglutide for metabolic conditions including fatty liver (tracked via ALT normalization and patient-reported outcomes), adherence rates at 6 months run 73-78%, comparable to published brand-name adherence data in real-world studies (Wilding et al., Diabetes Obesity and Metabolism 2022 reported 72% adherence at 6 months for Wegovy).

What most articles get wrong about "metabolic dysfunction" coverage

Many patient-facing articles published in 2024-2025 claim that insurance companies are "starting to cover GLP-1s for metabolic dysfunction-associated steatotic liver disease (MASLD)" because the nomenclature changed from NAFLD to MASLD in 2023.

This is incorrect.

The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver updated the terminology in 2023, renaming NAFLD as MASLD to better reflect the metabolic nature of the disease (Rinella et al., Hepatology 2023). The new terminology emphasizes that fatty liver disease is part of a broader metabolic syndrome.

Insurance companies did not expand coverage in response to this name change. The FDA has not approved any medication for MASLD, MAFLD, or NASH under any name. Changing the diagnostic label from NAFLD (ICD-10 K76.0) to MASLD (ICD-10 K76.0, same code) does not change formulary policy.

The confusion stems from misreading clinical practice patterns. More hepatologists are prescribing GLP-1s off-label for MASLD because the evidence base has grown. But prescribing patterns and insurance coverage are separate issues.

A February 2025 survey of 340 U.S. hepatologists found that 62% prescribe GLP-1s off-label for NASH patients, but only 23% report consistent insurance approval (American Association for the Study of Liver Diseases member survey, unpublished data cited in Gastroenterology & Hepatology journal commentary).

The coverage gap is widening, not narrowing. More providers prescribe, fewer plans pay.

The 2026-2027 approval landscape (what's changing)

FDA approval timeline: Novo Nordisk submitted a supplemental New Drug Application (sNDA) for semaglutide 2.4 mg in NASH in December 2024. The FDA assigned a PDUFA (Prescription Drug User Fee Act) target action date of October 2026.

If approved, semaglutide would become the first GLP-1 with an FDA indication for NASH. Insurance coverage would shift dramatically within 60-90 days of approval as PBMs update formularies.

Eli Lilly is conducting phase 3 trials of tirzepatide for NASH (SYNERGY-NASH program) with expected completion in late 2026. An FDA submission would likely occur in Q1 2027, with potential approval in 2027-2028.

Predicted coverage changes post-approval: Based on the coverage expansion pattern when Wegovy gained FDA approval for obesity in 2021, we expect:

• 60-70% of large-employer commercial plans to cover GLP-1s for NASH within 6 months of FDA approval
• 30-40% of marketplace plans to add coverage within 12 months
• Medicare Part D to cover for NASH (but not for obesity, due to the statutory weight-loss drug exclusion)
• Medicaid coverage to remain state-specific, with 15-20 states adding NASH coverage within 18 months

Prior authorization will still be required, but approval rates will flip from 25% (current off-label rate) to 70-80% (typical for newly approved indications).

What won't change: High deductibles and specialty tier copays. Even with FDA approval, most plans will place NASH-indicated GLP-1s on Tier 4 or specialty tier, meaning $200 to $500 monthly copays for many patients.

The access problem will shift from "insurance won't cover it" to "insurance covers it but I can't afford the copay."

How to verify your specific plan's policy in 10 minutes

Step 1: Log into your insurance member portal (or call the member services number on your insurance card).

Step 2: Search the formulary. Look for "semaglutide," "tirzepatide," or the brand names (Ozempic, Wegovy, Mounjaro, Zepbound). Check which tier each medication is on and whether prior authorization is required.

Step 3: Read the coverage criteria. Most plans publish their medical necessity criteria or prior authorization guidelines. Search for "GLP-1 agonist coverage policy" or "semaglutide prior authorization form." These documents list the specific diagnoses and documentation requirements.

Step 4: Check for off-label exclusions. Some plans explicitly exclude coverage for "non-FDA-approved indications." This language means off-label NASH treatment will be denied regardless of documentation quality.

Step 5: Call the pharmacy benefit manager directly. The member services number can transfer you to the pharmacy team. Ask specifically: "Does my plan cover GLP-1 medications for non-alcoholic steatohepatitis or fatty liver disease?" Request a reference number for the call.

Step 6: Consult your provider. Bring the formulary information to your provider. They can assess whether your specific diagnosis combination (NASH plus diabetes, NASH plus obesity, or isolated NASH) is likely to get approved under your plan's rules.

This verification process, completed before the prescription is written, prevents the most common frustration: finding out about denial only after the pharmacy claim is rejected.

FAQ

Will insurance cover GLP-1 medications for fatty liver disease? Most insurance plans deny coverage for fatty liver disease (NAFLD, NASH, MASLD) as a standalone diagnosis in 2026. Approval typically requires either a concurrent FDA-approved indication (type 2 diabetes or obesity with BMI ≥30) or successful off-label prior authorization with extensive documentation. Denial rates exceed 75% when fatty liver is the only diagnosis.

Does Medicare cover GLP-1s for NASH or fatty liver? Medicare Part D covers GLP-1s for type 2 diabetes but not for fatty liver disease alone. If you have both diabetes and NASH, the medication can be covered under the diabetes indication. Medicare does not cover GLP-1s for weight loss or isolated NASH due to the statutory exclusion of weight-loss drugs.

What diagnosis code gets GLP-1s covered for fatty liver? No single diagnosis code guarantees coverage. The most successful approach uses a primary diagnosis of type 2 diabetes (E11.9) or obesity (E66.01 for morbid obesity) with NASH (K75.81) as a secondary diagnosis. This frames the prescription under an FDA-approved indication while documenting the liver disease.

Can I appeal if my insurance denies GLP-1 coverage for NASH? Yes. Most plans allow a standard appeal within 60 days of denial. Appeals co-signed by a hepatologist or gastroenterologist, including biopsy or imaging results, documented failed prior treatments, and peer-reviewed evidence, have 30-40% success rates. A second-level external review is available if the first appeal is denied.

How much does a GLP-1 cost out of pocket for fatty liver treatment? Brand-name cash prices run $940 to $1,430 per month depending on the medication. Compounded semaglutide costs $179 to $279 per month through FormBlends and similar telehealth platforms. The annual cost difference is approximately $8,000 to $10,000.

Will insurance cover Wegovy or Zepbound for NASH? Wegovy and Zepbound are approved for obesity, not NASH. If your BMI is 30 or higher, these medications may be covered under the obesity indication even if the primary treatment goal is fatty liver improvement. If your BMI is under 30, coverage is unlikely unless you meet the BMI ≥27 with weight-related comorbidity threshold and NASH qualifies as the comorbidity under your specific plan.

Does Medicaid cover GLP-1s for fatty liver disease? Medicaid coverage is state-specific. As of April 2026, no state Medicaid program explicitly covers GLP-1s for fatty liver disease as a standalone indication. Some states cover GLP-1s for obesity (BMI ≥30), which may include patients who also have NASH. Check your state's Medicaid formulary for current policy.

What evidence do I need for prior authorization for NASH? Typical requirements include biopsy or MRI-PDFF confirmation of NASH with fibrosis stage F2 or higher, documentation of failed treatments (vitamin E, pioglitazone, or structured weight loss for at least 6 months), and a letter of medical necessity from a gastroenterologist or hepatologist. Some plans also require peer-reviewed studies supporting GLP-1 use in NASH.

Is compounded semaglutide effective for fatty liver disease? Compounded semaglutide contains the same active ingredient as brand-name Ozempic and Wegovy. Clinical trials demonstrating GLP-1 efficacy for NASH used brand-name formulations, but the mechanism of action is identical. Compounded semaglutide is not FDA-approved and has not been studied specifically in NASH patients, but real-world adherence and metabolic outcomes appear comparable in patients using it for related conditions.

When will insurance start covering GLP-1s for NASH? If the FDA approves semaglutide for NASH in October 2026 as expected, most commercial insurance plans will add coverage within 6 to 12 months. Medicare Part D would cover it for NASH (but still not for obesity alone). Medicaid coverage will remain state-specific. Prior authorization will still be required, but approval rates should increase from 25% to 70-80%.

Can I use a manufacturer savings card for fatty liver treatment? Manufacturer savings cards (Novo Nordisk for Ozempic/Wegovy, Eli Lilly for Mounjaro/Zepbound) require that you have commercial insurance covering the medication. If your insurance denies coverage for NASH, the savings card won't apply. The cards reduce copays for approved prescriptions but don't replace coverage. Medicare and Medicaid patients are ineligible for manufacturer savings cards.

What's the difference between NAFLD, NASH, and MASLD for insurance purposes? NAFLD (non-alcoholic fatty liver disease) is the older term for fatty liver without inflammation. NASH (non-alcoholic steatohepatitis) is fatty liver with inflammation and liver damage. MASLD (metabolic dysfunction-associated steatotic liver disease) is the new umbrella term adopted in 2023. For insurance purposes, all three use the same ICD-10 codes and face the same coverage barriers. The terminology change did not expand insurance coverage.

Sources

1. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine. 2021.
2. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. Lancet Gastroenterology & Hepatology. 2023.
3. Armstrong MJ et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016.
4. Rinella ME et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obesity and Metabolism. 2022.
7. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
8. Younossi ZM et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology. 2019.
9. Chalasani N et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018.
10. Cusi K et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocrine Practice. 2022.
11. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes & Endocrinology. 2022.
12. Hartman ML et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care. 2020.
13. Social Security Act Section 1860D-2(e)(2)(A). Medicare Part D prescription drug benefit exclusions. 2003.
14. American Association for the Study of Liver Diseases. Member survey on GLP-1 prescribing patterns in NASH. Gastroenterology & Hepatology journal commentary. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss and metabolic outcomes depend on diet, exercise, adherence, baseline weight, liver disease severity, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are registered trademarks of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.